Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:601572.
doi: 10.1155/2012/601572. Epub 2011 Jul 31.

The Role of C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases

Thomas Martini  1 , Roman Mayr, Emanuela Trenti, Salvatore Palermo, Evi Comploj, Armin Pycha, Maria Zywica, Michele Lodde
Affiliations

The Role of C-Choline-PET/CT-Guided Secondary Lymphadenectomy in Patients with PSA Failure after Radical Prostatectomy: Lessons Learned from Eight Cases

Thomas Martini et al. Adv Urol. 2012.

Abstract

Introduction. (11)C-choline-PET/CT is a promising technique for detection/restaging of patients with biochemical failure (BF) after curative therapy for prostate cancer (PCA). The aim of this paper was to evaluate the PSA response in patients with BF after radical prostatectomy (RP) who underwent secondary lymphadenectomy (LAD) due to (11)C-choline-PET/CT findings. Material and Methods. Eight patients with BF and positive lymph nodes in (11)C-choline-PET/CT after RP were retrospectively included in the study. Extended LAD until the common iliac arteries was performed in all patients. Results. Six of 8 patients had histologically proven lymph node metastases. Four patients showed an initial PSA reduction after LAD, and in 4 patients the PSA increased. Two of the latter had no histological lymph node metastases. Conclusions. Because 50% of our patients showed an initial PSA response, our data suggest that positive (11)C-choline-PET/CT after RP and BF could help to select patients that could benefit from secondary LAD.

PubMed Disclaimer

References

    1. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 1993;41(2):113–121. - PubMed
    1. Stein A, DeKernion JB, Dorey F. Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. British Journal of Urology. 1991;67(6):626–631. - PubMed
    1. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. Journal of Urology. 1993;150(6):1856–1859. - PubMed
    1. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. Journal of Urology. 2003;169(2):517–523. - PubMed
    1. Podo F. Tumour phospholipid metabolism. NMR in Biomedicine. 1999;12(7):413–439. - PubMed

LinkOut - more resources